This highly cited publication demonstrated a successful experimental clinical application of MSC-EVs where MSC-EVs decreased numbers of patient-derived peripheral blood cells, which secreted the pro-inflammatory cytokines IL-1β, TNFα and IFNγ, likely contributing modulating patient's immune status and significant improvement of clinical GvHD symptoms 38. Here, IFNG is linked to graft versus host disease.